Merck Sharp + Dohme Corp.

Merck Canada Inc.

Merck Sharp & Dohme LLC

Msd R&d Co., Ltd.

William D Shipe

Craig William Lindsley

Ian M Bell

James C Barrow

Christopher D Cox

Thomas J Greshock

Brendan M Crowley

John M Sanders

Peter J Manley

Andrew John Harvey

Richard Berger

Kenneth J Leavitt

Deodial Guy Guiadeen

Vanessa L Rada

Scott D Kuduk

Yimin Qian

Mark T Bilodeau

Michael P Dwyer

John A McCauley

Dong-Ming Shen

Shawn J Stachel

Peter D Williams

Deping Wang

Douglas C Beshore

Anthony W Shaw

Philippe G Nantermet

Daniel Vincent Paone

Oscar Miguel Moradei

B Wesley Trotter

Gregori J Morriello

David James Hallett

Izzat Tiedje Raheem

Jianmin Fu

Rajan Anand

Cory R Theberge

Brian T Campbell

Christopher James Bungard

Joseph Leslie Duffy

Christopher Joseph Sinz

Shimin Xu

Kausik K Nanda

Lehua Chang

David Jonathan Bennett

Christian Beaulieu

Vouy Linh Truong

Ronald K Chang

Keith P Moore

Zhiqiang Yang

Ashley Forster

Linda M Suen

Carmela Molinaro

Catherine M Wiscount

Christina Di Marco

Sheldon N Crane

Nathan R Kett

Yiwei Li

Yili Chen

John C Hartnett

Belinda C Huff

Satyanarayana Tummanapalli

Remond Moningka

Ming Wang

Zhigang Guo

Jesse J Manikowski

Amy Zartman

Jaime Lynn Bunda

Jeffrey Melamed

David Wisnoski

Daniel Mckay

ZhiQiang Yang

Yingjian Bo

Haitang Li

Chunmei Hu

Abdellatif El Marrouni

Yunlong Zhang

Christian Nadeau

Feng Yang

Joseph L Duffy

Antonella Converso

Cheng Wang

David N Hunter

Christopher J Sinz

Anthony J Roecker

Li Hao

Kate Holloway

Sanjay Kumar Singh

Sivalenka Vijayasaradhi

Mark B Nolt

Deodial G Guiadeen

John A Mccauley

Tummanapalli Satyanarayana

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

Tetrahydroquinazoline derivatives as selective cytotoxic agents

The present disclosure is directed to cyclohexylglycine derivatives of Formula I and their use as HIV-infected cell kill agents which accelerate the death of HIV GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells.

Cyclohexylglycine derivatives as selective cytotoxic agents

The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I). 

Heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula (I) that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation. 

Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors

The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction. 

6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation 

Allosteric modulators of nicotinic acetylcholine receptors

The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

HIV protease inhibitors

The present invention is directed to triazolopyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Triazolopyridinone PDE10 inhibitors

The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

Imidazolyl methyl piperidine T-type calcium channel antagonists

The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Alkoxy pyrimidine PDE10 inhibitors

The present invention is directed to 4-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

4-fluoro-piperidine T-type calcium channel antagonists

The present invention is directed to quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders, and to novel M1 receptor positive allosteric modulator compounds of formulae (II) to (VIII). The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases in which the M1 receptor is involved.

Quinolone M1 receptor positive allosteric modulators

The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.

Quinolone neuropeptide S receptor antagonists

The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

4-OXO,1-4-dihydroquinoline M1 receptor positive allosteric modulators

Growing community of inventors

Chalfont, PA, United States of America

William D Shipe